Kobayashi Pharmaceutical Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 8 analysts
Updated 2026/10/01Earnings Calendar
Updated 2026/10/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/05 | ¥24.21 | ¥1.34 | -94.5% |
| 2026/05/07 | ¥5.38 | ¥13.95 | +159.3% |
| 2026/02/09 | ¥81.80 | ¥-42.41 | -151.9% |
| 2025/11/10 | ¥43.93 | ¥48.99 | +11.5% |
Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
735.8K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
498.7K | +0.79% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
365.5K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
182.1K | -6.66% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Equity ETF
|
122.2K | +2.84% | |
|
College Retirement Equities Fd.-College Retirement Equities Fd. - Tota
|
120.8K | +2.45% |
Dividend History
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥45 | -56.7% |
| 2025 | ¥104 | +2.0% |
| 2024 | ¥102 | +1.0% |
| 2023 | ¥101 | +12.2% |
| 2022 | ¥90 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥155,252M | ¥166,258M | ¥173,455M | ¥165,600M |
| Gross Profit | ¥88,773M | ¥92,331M | ¥96,375M | ¥87,603M |
| Operating Income | ¥26,071M | ¥26,674M | ¥25,784M | ¥24,869M |
| Pretax Income | ¥27,654M | ¥27,968M | ¥27,588M | ¥13,942M |
| Net Income | ¥19,715M | ¥20,022M | ¥20,338M | ¥10,067M |
| EPS | ¥252.36 | ¥259.59 | ¥268.16 | ¥135.42 |
| Operating Margin | 16.79% | 16.04% | 14.86% | 15.02% |
| Balance Sheet | ||||
| Total Assets | ¥252,554M | ¥255,827M | ¥267,473M | ¥265,368M |
| Total Equity | ¥195,599M | ¥197,899M | ¥204,816M | ¥213,466M |
| Total Liabilities | ¥56,955M | ¥57,928M | ¥62,657M | ¥51,902M |
| Cash | ¥95,024M | ¥96,233M | ¥71,536M | ¥50,873M |
| Interest-bearing Debt | ¥630M | ¥792M | ¥987M | ¥846M |
| Equity Ratio | 77.45% | 77.36% | 76.57% | 80.44% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥22,419M | ¥31,914M | ¥18,360M | ¥11,246M |
| Investing CF | ¥7,991M | -¥14,312M | -¥19,576M | -¥18,415M |
| Financing CF | -¥10,377M | -¥20,759M | -¥19,463M | -¥7,768M |
| Free CF | ¥18,234M | ¥15,685M | ¥4,791M | -¥15,383M |
| Efficiency | ||||
| ROE | 10.08% | 10.12% | 9.93% | 4.72% |
| ROA | 7.81% | 7.83% | 7.60% | 3.79% |
Latest IR Information
-
Contact for this matter
Denying reports by certain media about delisting. No decisions have been made at this time, and if any material facts arise that should be disclosed, they will be announced promptly.
Read more -
2026 Consolidated Interim Financial Results for the 2nd Quarter (Mid-Term) under Japanese GAAP
Net sales for the interim period were ¥70,749 million, up 2.5% year over year. Operating income was ¥2,162 million, down 67.5% YoY. Ordinary income was ¥3,006 million, down 58.5% YoY. Net income attributable to owners of the parent was ¥1,136...
Read more -
Notice of Change in Consolidated Subsidiaries Due to Share Transfer
Transfer of all shares of Jiangsu Kobayashi Pharmaceutical Co., Ltd. to Wantianwan Techan Pharmaceutical (Xiamen) Co., Ltd. The share ownership before and after transfer will be 100% → 0%, with the closing date planned for the end of October 2026....
Read more -
[Kobayashi Pharmaceutical] Q1 2026 Earnings Results | Sales of ¥33.6 billion (+3.2%)
Kobayashi Pharmaceutical's Q1 2026 recorded sales of ¥33.6 billion (YoY +3.2%), with net profit decreasing to approximately ¥1.0 billion. Healthcare and daily用品 are showing signs of recovery, but profits have declined. Continued attention to business performance is warranted.
Read more -
Approach and Policy Regarding the Reduction of Investment Unit
Kobayashi Pharmaceutical Co., Ltd. recognizes that reducing the investment unit is an effective measure to expand the investor base and revitalize the stock market, and has indicated a policy to consider this appropriately based on future market trends.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥5,521
Rating Score: 3.00 (Based on 8 analysts)
※1=Strong Buy, 5=Strong Sell
Staggering 20 Billion Yuan Loss: The Controversial "Japanese Miracle Drug" Goes Up for Sale - 36Kr ↗
Company Information
About
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
